Taysha Gene Therapies annual r&d spending
2020
2021
2022
2023
2024
2025
Taysha Gene Therapies R&D Spending Growth & History (TSHA)
Taysha Gene Therapies's r&d spending was $86.4M for fiscal 2025.
View full Taysha Gene Therapies company overviewTaysha Gene Therapies annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $86.4M | $20.4M | +30.91% |
| 2024 | 2024-12-31 | $66.0M | $9.2M | +16.24% |
| 2023 | 2023-12-31 | $56.8M | −$34.4M | −37.72% |
| 2022 | 2022-12-31 | $91.2M | −$40.8M | −30.90% |
| 2021 | 2021-12-31 | $131.9M | $100.0M | +313.71% |
| 2020 | 2020-12-31 | $31.9M | — | — |
Taysha Gene Therapies quarterly r&d spending
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $38.6M | $18.5M | +91.83% |
| Q1 2026 | 2026-03-31 | $33.8M | $18.2M | +117.21% |
| Q4 2025 | 2025-12-31 | $25.0M | $9.6M | +62.82% |
| Q3 2025 | 2025-09-30 | $25.7M | $10.8M | +72.25% |
| Q2 2025 | 2025-06-30 | $20.1M | $5.1M | +33.62% |
| Q1 2025 | 2025-03-31 | $15.6M | −$5.1M | −24.65% |
| Q4 2024 | 2024-12-31 | $15.3M | $2.6M | +20.84% |
| Q3 2024 | 2024-09-30 | $14.9M | $3.2M | +26.76% |
| Q2 2024 | 2024-06-30 | $15.1M | −$4.7M | −23.84% |
| Q1 2024 | 2024-03-31 | $20.7M | $8.1M | +65.07% |
| Q4 2023 | 2023-12-31 | $12.7M | −$25,000 | −0.20% |
| Q3 2023 | 2023-09-30 | $11.8M | −$5.0M | −29.71% |
| Q2 2023 | 2023-06-30 | $19.8M | −$3.7M | −15.80% |
| Q1 2023 | 2023-03-31 | $12.5M | −$25.7M | −67.23% |
| Q4 2022 | 2022-12-31 | $12.7M | −$25.2M | −66.49% |
| Q3 2022 | 2022-09-30 | $16.8M | −$22.8M | −57.56% |
| Q2 2022 | 2022-06-30 | $23.5M | −$7.1M | −23.29% |
| Q1 2022 | 2022-03-31 | $38.2M | $14.3M | +60.07% |
| Q4 2021 | 2021-12-31 | $37.9M | $25.7M | +209.28% |
| Q3 2021 | 2021-09-30 | $39.5M | $28.5M | +257.49% |
| Q2 2021 | 2021-06-30 | $30.6M | $27.6M | +900.75% |
| Q1 2021 | 2021-03-31 | $23.9M | $18.3M | +332.61% |
| Q4 2020 | 2020-12-31 | $12.3M | $11.3M | +1142.15% |
| Q3 2020 | 2020-09-30 | $11.1M | — | — |
| Q2 2020 | 2020-06-30 | $3.1M | — | — |
| Q1 2020 | 2020-03-31 | $5.5M | — | — |
| Q4 2019 | 2019-12-31 | $987,000 | — | — |
Taysha Gene Therapies r&d spending trends
Over the last five fiscal years, Taysha Gene Therapies's r&d spending increased from $31.9M to $86.4M, a change of $54.5M. The latest reported quarter, Q2 2026, shows $38.6M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Taysha Gene Therapies source filings ↗